-
J Neurosci: Study reveals the neurological principles behind tickling behavior.
Time of Update: 2020-09-27
September 9, 2020 /--- According to a recent study based on mouse models published in journal of Neuroscience, rubbing the skin can effectively activate the itch-stopping signaling pathway in the nerves of the spinal cord.
-
Nature: Heavy! The intestinal bacterios may worsen the symptoms of the disease in patients with multiple sclerosis!
Time of Update: 2020-09-26
10, 2020 // -- In a recent study published in the international journal Nature, scientists from the Japan Institute of Science and Chemistry and others found that special microbial combinations in the gut may accelerate the deterioration of symptoms of multiple sclerosis mouse model disease, and researchers say these two specific intestinal bacteriocytes may enhance the activity and ability of immune cells to attack the patient's own brain and spinal cord.
-
Nat Commun: The study reveals the mechanisms of memory formation and maintenance.
Time of Update: 2020-09-26
its findings also provide new insights into how people form expectations and make accurate predictions about what might happen in the future.
-
First secondary progressive multiple sclerosis (SPMS) oral drug! Novarma Mayzent improves cognition and slows the progression of disability and is listed in China!
Time of Update: 2020-09-26
Over time, up to 50-60% of RRMS patients will develop into SPMS, and Mayzent ® is a next-generation, selective 1-phosphate pyrethroid (S1P) regulator, the world's first approved oral disease correction therapy (DMT) drug for SPMS, and early on on treatment can effectively slow progression and cognitive decline in disability.
-
20 years of great innovation! Lilly 5-HT1F Agonist Reyvow New Phase III Study: Take the drug for 1 hour and the pain disappears for 48 hours!
Time of Update: 2020-09-26
!--,2020 // -- Eli Lilly recently presented the results of a new Phase III clinical study on the evaluation of the oral drug Reyvow (lasmitan) C-V tablet for the treatment of migraine attacks in adult patients at the PAINWeek®2020 Real-Time Virtual Conference.
-
Injection twice a year! Roche B cell therapy Ocrevus treats multiple sclerosis: significantly effective in a wide range of patients!
Time of Update: 2020-09-26
data released at this meeting were as follows: (1) In the main analysis of the CASTING study, about 75% of RRMS patients (492/658) showed no signs of disease activity (NEDA; brain injury, recurrence and disability deterioration) for 2 years after switching to Ocrevus treatment twice a year (pre-specified MRI reblinization at 8 weeks).
-
Science Sub-Journal: Significant Progress! Revealed C9orf72 poly (GR) aggregation induces TDP-43 protein lesions.
Time of Update: 2020-09-26
TDP-43 (TAR DNA-binding protein 43) enumeration is a pathological feature of FTD and ALS, including cases caused by repeated amplification of G4C2 in the C9orf72 gene (c9FTD/ALS).
study was recently published in the journal Science Translational Medicine under the title "C9orf72 poly (GR) aggregation induces TDP-43 proteinopathy".
-
New drugs for depression! Caplyta Assisted Treatment of Bisteal Depression Phase III Success: Significantly Improves Depressive Symptoms and Severity!
Time of Update: 2020-09-26
, the company recently published positive top-line results from a Phase III clinical trial that evaluated Capallyta as an ad-assisted therapy for lithium salts or valproates to treat severe depressive episodes associated with biphasic type I or bisych type II disorder.
-
Rare pediatric epilepsy new drug! Fintepla (Finteplamin) Treatment of Dravet Syndrome Phase 3 Phase III Clinical: Significant reduction in convulsive seizures!
Time of Update: 2020-09-26
results showed that the study achieved the main goal: patients in the Fintepla 0.7mg/kg/day group had an average monthly reduction in convulsive seizures by 64.8% compared to the placebo group.
-
Innovative drug for multiple sclerosis! Novart's off-the-skin injection-targeted B-cell therapy Kesimpta has significant efficacy in newly diagnosed patients!
Time of Update: 2020-09-26
Kesimpta is a new targeted B-cell therapy approved by the FDA in August as a subcute injection for the treatment of adult multiple sclerosis (RMS), including clinical isolation syndrome, relapsed remission-relieving diseases, and active secondary progressive diseases.
-
A study of 20,000 people at Oxford University suggests that blood pressure alters the structure of the brain.
Time of Update: 2020-09-26
study found that high blood pressure and diabetes can adversely affect thinking speed and memory in a healthy brain population, especially as blood pressure rises and cognitive performance gets worse.
team concluded that in relatively healthy people, cerebrovascular risk factors can also affect brain structure and cognitive function.
-
Sci Adv: A neurological link between the immune system and insomnia.
Time of Update: 2020-09-26
their study in mice linked neuron connections that trigger insomnia to changes in the immune system caused by stress, which in turn weakened the body's defenses against multiple threats.
-
Sci Trans Med: New research could help treat Parkinson's.
Time of Update: 2020-09-26
" combination of medical practice to laboratory research to computer science can we understand the cause and identify the active substances that may be used for treatment at the same time," explains Professor Rejko Krüger, a professor at the University of London.
-
New drug for Parkinson's disease! The third generation of powerful COMT inhibitor Ongentys significantly improved movement fluctuations, Fosun Pharma introduced to China!
Time of Update: 2020-09-26
a separate post-mortem analysis showed that in patients recently diagnosed with parkinson's disease with motor fluctuations, when used as the first COMT inhibitor as an additional therapy for lyso-doba/carbidoba, entacap Ongentys significantly increased the absolute "ON" time by 1 hour (12 ;p4 minutes .
-
New oral medicine for multiple sclerosis! Next-generation immunomodulant IMU-838: Rapid suppression of MRI lesions, significant efficacy, high safety!
Time of Update: 2020-09-26
As mentioned earlier, the study reached its main endpoint: within 24 weeks of treatment, the cumulative number of combined independent active magnetic resonance imaging (CUA-MRI) lesions in patients in the 45 mg dose group decreased significantly by 62% compared to the placebo group.
-
Neuron: What exactly is hearing loss that causes Alzheimer's disease?
Time of Update: 2020-09-26
Photo Source: CC0 Public Domain In an epidemiological study, researchers found that hearing loss is associated with dementia, and that the condition causes one-tenth of the 47 million cases of dementia worldwide; in this study, researchers proposed a new theory to reveal why ear impairments induce Alzheimer's disease, an explanation that researchers hope will help scientists delve deeper into the pathogenesis of Alzheimer's disease and effectively predict the risk of developing alzheimer's disease in the future.
-
Sci Rep: Ten-minute massage helps relieve body stress.
Time of Update: 2020-09-26
findings, published September 8, 2020 in the journal Scientific Reports, are the first to show that relaxing the side-sensing nervous system (PNS) can be effective in reducing stress at the psychological and physiological levels.
-
Sci Adv: Reveals the molecular mechanism by which transons regulate neuron differentiation and nerve transfer activity in the human brain.
Time of Update: 2020-09-26
September 10, 2020 // -- The human gene contains more than 4.5 million DNA components called transontrovirals, virus-like components that jump through the genome and help regulate gene expression, whi
-
JCI: How chronic stress leads to bone loss.
Time of Update: 2020-09-26
they found that the central nervous circuit from the frontal to the lower pasum brain mediates chronic stress-induced bone loss through the surrounding sensory nervous system.
Original source: Fan Yang et al, A GABAergic neural circuit in the ventromedial hypothalamus mediates chronic-stressed bone loss, Journal of Clinical Investigation (2020).
-
Nature: Alcoholism can cause brain volume to shrink.
Time of Update: 2020-09-26
Researchers first collated the relevant scientific reports of the past 10 years, different studies on the monitoring of brain volume, resulting in some differences in results, but the general conclusion is that alcohol abuse will cause different degrees of brain function area atrophy, but the gender impact of men and women there are different degrees of difference.
